Organon & Co (OGN) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Total Cash From Operating Activities Chart for Organon & Co
Organon & Co (OGN) operating cash flow for FY2025 was USD 700.0M, a -25.5% change from FY2024. Organon & Co's operating cash flow grew from USD 3.4B in 2017 to USD 700.0M in 2025 (-79.5% over 8 years). Operating cash flow compound annual growth rate: 5-year CAGR of -20.4%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.61B
- Implied Share Price
- $13.75
- Enterprise Value
- $11.01B
- Revenue (TTM)
- $6.13B
- EBITDA
- $1.56B
- Profit Margin
- 3.41%
- Trailing P/E
- 17.63
- Forward P/E
- 5.09
- Price/Book (MRQ)
- 3.57
- Price/Sales (TTM)
- 0.59
- EV/EBITDA
- 8.39
- EV/Revenue
- 1.80
- Dividend Yield
- 0.58%
- Book Value
- $3.83
- Free Cash Flow (FY2025)
- $538.00M
- Free Cash Flow Yield
- 14.90%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.